Breast Cancer
Conditions
Keywords
PPAR-gamma, estrogens, NSAIDS, polymorphism, metabolomics
Brief summary
Postmenopausal women, stratified by a peroxisome proliferator-activated receptor gamma-2 (PPARG) polymorphism, were given the following treatments in a random order with a 5w wash-out period: a 400mg ibuprofen tablet or a placebo tablet; both treatments were followed after 30min by a single acute dose of 0.4g alcohol per kg bw. Serum estrogen levels were measured before and at three timepoints after alcohol intake. It is hypothesized that the acute decrease in estrogen sulphate and other markers of estrogens after alcohol intake is modulated by ibuprofen and by PPARG genotype.
Detailed description
In a pilot human intervention trial we aimed to determine the effect of the PPARG Pro12Ala polymorphism and the PPARγ stimulator, Ibuprofen, on sex-hormone levels following alcohol intake in postmenopausal women. Seven women with PPARG Pro12Ala and 18 PPARG wildtype women were included.The study was performed as a randomised, double-blinded, placebo controlled 2x24 h crossover study. The volunteers were randomised to 1 of 2 groups who got the two treatments in different orders. Treatment 1 was a placebo tablet with water followed after 30min by an alcoholic drink providing 0,4g alcohol per kilogram bw and treatment 2 was an Ibuprofen tablet (400mg) with water followed by the same alcoholic drink. The two treatments were separated by a 5-7 weeks washout period. Alcohol was supplied as 7.7% ethanol in a lime-flavoured drink and was consumed over 15 min. EDTA-plasma was collected 40min before and 30, 60 and 90 min after ethanol intake as well as after 24 hours. Ibuprofen (400mg) was provided together with 100mL water 30min before the ethanol. Urine was collected throughout the 24 hour interval. Serum estrone, estrone sulphate, serum estrogen-binding globulin (SHBG), and ethanol were determined. It is hypothesized that the acute decrease in estrogen sulphate and other markers of estrogens after alcohol intake is modulated by ibuprofen and by PPARG genotype.
Interventions
DRUGIbuprofen Tab 400 MG
400mg ibuprofen is provided and an alcohol challenge (0.4g/kg bw) is given 30min later
DRUGPlacebo tab
A placebo tablet is provided and an alcohol challenge (0.4g/kg bw) is given 30min later
Sponsors
Technical University of Denmark
Professor Lars Ove Dragsted
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Intervention model description
Participants are randomized to an ibuprofen or placebo pill in the first period and are then provided with placebo or ibuprofen pills, respectively, in the second period in a crossover fashion. Alcohol (0.4g/kg bw) is provided as a challenge 30min after the pill has been swallowed.
Eligibility
Sex/Gender
FEMALE
Age
50 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
1. postmenopausal (last menses at least 1 year earlier); 2. having a weekly alcohol use of less than 14 drinks 3. having a BMI of 18-35;
Exclusion criteria
1. a history of alcohol abuse 2. alcohol abstaining 3. history of hysterectomy before last menses with preservation of both ovaries (unless a medical confirmation for the postmenopausal status exists or the participant is 60 years or older); 4. major health problems, such as ulcers, heart diseases, diabetes or cancer 5. previous or current use of HRT 6. taking prescription medications that could interfere with the study (i.e. daily use of NSAIDs and/or medication that interact with PPARγ e.g. cholesterol lowering medicine); 7. being allergic to alcohol and/or Ibuprofen 8. smoking
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Serum estrone sulphate (pmol/l) | from 40 min before to 90 min after alcohol consumption | Plasma estrone sulfate concentration after acute ethanol intake by Ibuprofen intake and/or PPARG genotype |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Serum estrone (pmol/l) | from 40 min before to 90 min after alcohol consumption | Plasma estrone decrease after acute ethanol intake by ibuprofen intake and/or PPARG genotype |
| Serum SHBG (nmol/l) | from 40 min before to 90 min after alcohol consumption | Plasma SHBG concentration after acute ethanol ingestion by ibuprofen intake and/or PPARG genotype |
| Serum ethanol (g/l) | from 40 min before to 90 min after alcohol consumption | Plasma ethanol concentration after acute ethanol ingestion |
| Serum metabolomics (relative metabolite intensity) | from 40 min before to 24h after alcohol intake | The plasma metabolome profile by time after alcohol intake |
| Urine metabolomics (relative metabolite intensity) | from 40 min before to 24h after alcohol intake | The urine metabolome profile by time after alcohol intake |
Countries
Denmark
Outcome results
None listed